Abstract
HMGI and HMGY are splicing variants of the HMGI(Y) gene and together with HMGI-C, belong to a family of DNA binding proteins involved in maintaining active chromatin conformation and in the regulation of gene transcription. The expression of the HMGI(Y) gene is maximal during embryonic development, declines in adult differentiated tissues and is reactivated in most transformed cells in vitro and in many human cancers in vivo. The HMGI(Y) genomic locus is frequently rearranged in mesenchymal tumours, suggesting a biological role for HMGI(Y) gene products in tumour biology. HMGIs are both target and modulators of retinoic acid activity. In fact, HMGI(Y) gene expression is differentially regulated by retinoic acid in retinoid-sensitive and -resistant neuroblastoma cells, while HMGI-C participates in conferring retinoic acid resistance in some neuroblastoma cells. In this paper we show that HMGI and HMGY isoforms are equally regulated by retinoic acid in neuroblastoma cell lines at both RNA and protein levels. More importantly our immunohistochemical analysis shows that, although HMGI(Y) is expressed in all neuroblastic tumours, consistently higher levels are observed in less differentiated neuroblastomas compared to more differentiated ganglioneuromas, indicating that HMGI(Y) expression should be evaluated as a potential diagnostic and prognostic marker in neuroblastic tumours. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abe N, Watanabe T, Sugiyama M, Uchimura H, Chiappetta G, Fusco A and Atomi Y (1999 Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res 59: 1169–1174
Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM, O’Brien M, Murphy RF and Balis FM (1997 Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol 15: 3330–3337
Albemayor E and Sidell N (1989 Human neuroblastoma cell lines as model for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect 80: 3–15
Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G and Ono SJ (2000 Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem 275: 14394–14400
Bandiera A, Bonifacio D, Manfioletti G, Mantovani F, Rustighi A, Zanconati F, Fusco A, Di Bonito L and Giancotti V (1998 Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 58: 426–431
Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM and Fusco A (1999 The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 59: 4793–4797
Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Giancotti V and Fusco A (1995 Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 15: 1545–1553
Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O and Myklebost O (1997 HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene 14: 2935–2941
Bolande RP (1985 Spontaneous regression and cytodifferentiation of cancer in early life: The oncogenic grace period. Suev Synth Path Res 4: 296–311
Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG, Lee CP and Evans AE (1997 Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 31: 49–55
Bustin M and Reeves R (1996 High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 54: 35–100
Castleberry RP (1997 Neuroblastoma. Eur J Cancer 33: 1430–1437, 1437–1438
Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V and Fusco A (1995 The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 10: 1307–1314
Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A and Fusco A (1996 High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13: 2439–2446
Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V and Fusco A (1998 Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 58: 4193–4198
Cmarik JL, Li Y, Ogram SA, Min H, Reeves R and Colburn NH (1998 Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not-resistant cells. Oncogene 16: 3387–3396
Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santoro M, Giancotti V and Fusco A (1996 Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 56: 1896–1901
Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, Sitarz AL and Hammond GD (1992 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med Pediatr Oncol 20: 307–311
Friedmann M, Holth LT, Zoghbi HY and Reeves R (1993 Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 21: 4259–4267
Giancotti V, Pani B, D’Andrea P, Berlingieri MT, Di Fiore PP, Fusco A, Vecchio G, Philp R, Crane-Robinson C and Nicolas RH (1987 Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c-myc and polyoma middle T genes. Embo J 6: 1981–1987
Giancotti V, Bandiera A, Ciani L, Santoro D, Crane-Robinson C, Goodwin GH, Boiocchi M, Dolcetti R and Casetta B (1993 High-mobility-group (HMG) proteins and histone H1 subtypes expression in normal and tumor tissues of mouse. Eur J Biochem 213: 825–832
Giannini G, Dawson MI, Zhang X and Thiele CJ (1997 Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells. J Biol Chem 272: 26693–26701
Giannini G, Di Marcotullio L, Ristori E, Zani M, Crescenzi M, Scarpa S, Piaggio G, Vacca A, Peverali FA, Diana F, Screpanti I, Frati L and Gulino A (1999 HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness. Cancer Res 59: 2484–2492
Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J and Hameister H (1998 The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 23: 350–357
Holth LT, Thorlacius AE and Reeves R (1997 Effects of epidermal growth factor and estrogen on the regulation of the HMG-I/Y gene in human mammary epithelial cell lines. DNA Cell Biol 16: 1299–1309
Ishwad CS, Shriver MD, Lassige DM and Ferrell RE (1997 The high mobility group I-C gene (HMGI-C): polymorphism and genetic localization. Hum Genet 99: 103–105
Johnson KR, Lehn DA and Reeves R (1989 Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 9: 2114–2123
Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP and Cohn SL (1998 Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience – a pediatric oncology group study. J Clin Oncol 16: 2007–2017
Kazmierczak B, Rosigkeit J, Wanschura S, Meyer-Bolte K, Van de Ven WJ, Kayser K, Krieghoff B, Kastendiek H, Bartnitzke S and Bullerdiek J (1996 HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: a survey of 30 tumors. Oncogene 12: 515–521
Kottickal LV, Sarada B, Ashar H, Chada K and Nagarajan L (1998 Preferential expression of HMGI-C isoforms lacking the acidic carboxy terminal in human leukemia. Biochem Biophys Res Commun 242: 452–456
Manfioletti G, Giancotti V, Bandiera A, Buratti E, Sautiere P, Cary P, Crane-Robinson C, Coles B and Goodwin GH (1991 cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res 19: 6793–6797
Matsuo T and Thiele CJ (1998 p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 16: 3337–3343
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB and Reynolds CP (1999 Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 341: 1165–1173
Pedeutour F, Quade BJ, Sornberger K, Tallini G, Ligon AH, Weremowicz S and Morton CC (2000 Dysregulation of HMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14. Genes Chromosomes Cancer 27: 209–215
Rommel B, Rogalla P, Jox A, Kalle CV, Kazmierczak B, Wolf J and Bullerdiek J (1997 HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk Lymphoma 26: 603–607
Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H and Van de Ven WJ (1995 Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10: 436–444
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY and Hammond D (1985 Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111–1116
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK and Castleberry RP (1999 The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86: 364–372
Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM and Schalken JA (1996 A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer 74: 573–578
Thiele CJ (1991a Biology of pediatric peripheral neuroectodermal tumors. Cancer Met Rev 10: 3119
Thiele CJ (1991b Pediatric peripheral neuroectodermal tumors, oncogenes and differentiation. Cancer Invest 8: 629–639
Thiele CJ, Reynolds CP and Israel MA (1985 Decreased expression of N-myc precedes retinoic acid induced morphological differentiation of human neuroblastoma. Nature 313: 404–406
Zhou X, Benson KF, Ashar HR and Chada K (1995 Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376: 771–774
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Giannini, G., Kim, C., Marcotullio, L. et al. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. Br J Cancer 83, 1503–1509 (2000). https://doi.org/10.1054/bjoc.2000.1494
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1494
Keywords
This article is cited by
-
A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors
Oncogene (2021)
-
High-mobility group AT-hook 1 promotes cardiac dysfunction in diabetic cardiomyopathy via autophagy inhibition
Cell Death & Disease (2020)
-
Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors
Cell Death & Disease (2014)
-
Regulation of microRNA expression by HMGA1 proteins
Oncogene (2009)
-
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death
Oncogene (2008)